CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement

British Journal of Clinical Pharmacology

Volumn 70, Issue 2, 2010, Pages 234-240

  Cen, Han Jing ^a,b   Zeng, Wu Tao ^a   Leng, Xiu Yu ^a   Huang, Min ^a   Chen, Xiao ^a   Li, Jia Li ^a   Huang, Zhi Ying ^a   Bi, Hui Chang ^a   Wang, Xue Ding ^a   He, Yan Ling ^b   He, Fan ^b   Zhou, Rui Na ^a   Zheng, Qi Shan ^a   Zhao, Li Zi ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

Author keywords

Chinese; CYP2C9; CYP4F2; mechanical heart valve replacement; VKORC1; warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; UNCLASSIFIED DRUG; WARFARIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEART VALVE PROSTHESIS; HEART VALVE REPLACEMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HEART VALVE PROSTHESIS IMPLANTATION; HEART VALVES; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; SEQUENCE ANALYSIS, DNA; WARFARIN;

EID: 77954508907     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03698.x     Document Type: Article

References (29)

1. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, Charng MJ, Lu MJ, Hung CR, Wei CY, Chen CH, Wu JY, Chen YT. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 2005 14 : 1745 1751.
2. Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, Amariglio N, Cohen Y, Ken-Dror G, Almog S, Gak E. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 2007 109 : 2477 2480.
3. Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 2008 82 : 495 500.
4. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E. VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 2008 111 : 3903 3904.
5. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 2005 3 : 137 145.
6. Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008 83 : 460 470.
7. Powell PK, Wolf I, Jin R, Lasker JM. Metabolism of arachidonic acid to 20-hydroxy-5,8,11, 14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J Pharmacol Exp Ther 1998 285 : 1327 1336.
8. Sontag TJ, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. J Biol Chem 2002 277 : 25290 25296.
9. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. Cyp4f2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433m variant. Mol Pharmacol 2009 75 : 1337 1346.
10. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, Bramanti P, Novelli G. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 2009 10 : 261 266.
11. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, Hubbard J, Turpaz Y, Langaee TY, Eby C, King CR, Brower A, Schmelzer JR, Glurich I, Vidaillet HJ, Yale SH, Qi Zhang K, Berg RL, Burmester JK. CYP4F2 genetic variant alters required warfarin dose. Blood 2008 111 : 4106 4112.
12. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009 5 : e1000433.
13. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005 165 : 1095 1106.
14. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976 3 : 2303 2308.
15. Obayashi K, Nakamura K, Kawana J, Ogata H, Hanada K, Kurabayashi M, Hasegawa A, Yamamoto K, Horiuchi R. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 2006 80 : 169 178.
16. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 1996 6 : 341 349.
17. The International HapMap Consortium. The International HapMap Project. Nature 2003 426 : 789 796.
18. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008 112 : 1022 1027.
19. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 2007 8 : 1545 1550.
20. Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 2007 5 : 8 16.
21. Larramendy-Gozalo C, Yang JQ, Verstuyft C, Bodin L, Dubert L, Zhang Y, Xu C, Fan L, Jaillon P, Becquemont L. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population. Basic Clin Pharmacol Toxicol 2006 98 : 611 613.
22. Wiwanitkit V. Pharmacogenomic effect of cytochrome P450 2C9 polymorphisms in different populations. Clin Appl Thromb Hemost 2006 12 : 219 222.
23. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, Ojopi EB, Dias-Neto E, Suarez-Kurtz G. Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin Pharmacol Ther 2008 84 : 722 728.
24. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK. Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 2004 14 : 539 547.
25. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004 91 : 87 94.
26. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006 79 : 291 302.
27. Wang TL, Li HL, Tjong WY, Chen QS, Wu GS, Zhu HT, Hou ZS, Xu S, Ma SJ, Wu M, Tai S. Genetic factors contribute to patient-specific warfarin dose for Han Chinese. Clin Chim Acta 2008 396 : 76 9.
28. Miao L, Yang J, Huang C, Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 2007 63 : 1135 1141.
29. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Commun 1999 254 : 628 631.